Reasons for Increases in Complications of Diabetes by Buse, J.B.
Corresponding Author: Desmond T. Jumbam, MSGH, Program in Global
Surgery and Social Change, Harvard Medical School, 641 Huntington Ave,
Boston, MA 02115 (desmond.jumbam@gmail.com).
Conflict of Interest Disclosures: None reported.
1. Dieleman JL, Micah AE, Murray CJL. Global health spending and
development assistance for health. JAMA. 2019;321(21):2073-2074.
doi:10.1001/jama.2019.3687
2. Dieleman JL, Hanlon M. Measuring the displacement and replacement of
government health expenditure. Health Econ. 2014;23(2):129-140. doi:10.1002/
hec.3016
3. Claeson M. The Global Financing Facility—towards a new way of financing for
development. Lancet. 2017;389(10079):1588-1592. doi:10.1016/S0140-6736
(17)31000-0
4. World Health Organization. Health Systems Financing: The Path to Universal
Coverage. https://www.who.int/whr/2010/en/. Accessed May 14, 2019.
In Reply Ongoing development of robust, sustainable, and
equitable health systems will require investment of domestic
resources, particularly government resources. Nonetheless,
recent forecasts of gross domestic product, government spend-
ing, and government health spending suggest that for the poor-
est countries in the world, funding the health system exclu-
sively with domestic resources may remain challenging.1 While
development assistance is one avenue to generate more re-
sources for health,2 Mr Jumbam and colleagues are right to
point out that there is evidence that DAH has in the past sys-
tematically depressed domestic government spending on
health, and this substitution should remain a concern to those
hoping to catalyze health gains.3,4
While there is evidence that donor funding can “crowd out”
domestic government funding, and economic theory explains
that this substitution may be “rational,” important questions re-
main. First and foremost, it is critical to know if and how in the
future DAH and government health spending can work to-
gether as complements rather than substitutes. Potential meth-
ods to achieve donor and government funding complementar-
ity would be to provide development assistance so that it is
dependent on and coordinated with “counterpart financing,” as
is Global Fund for AIDS support,5 or so that it targets global pub-
lic goods that have transnational effects but are generally out-
side of the purview of any particular country. In addition, pay-
for-performance schemes and arrangements like those modeled
by the Global Financing Facility aim to ensure complementar-
ity and improve the quality of services delivered.
In addition, it is important to further test the assertion that
DAH is, as it is provided at the moment, still crowding out gov-
ernment funding to the health sector. Previous research on this
topic relied on data that extended through 2006 and 2010, and
global health financing continues to evolve.3,4 If substitution
persists, it is also important to measure where government
health funds are being displaced. Reallocation of govern-
ment funds to allied sectors such as education or poverty re-
duction programs may still lead to health gains, albeit through
a different mechanism.
Moving forward, it is important to reflect on the fact the
current funding for health in many low-income countries is
not enough, and that funding in many lower-middle-income
countries relies too much on out-of-pocket spending, such that
resources are not equitably disbursed and major health events
can lead to impoverishment. Raising more resources for health
in these countries, to be paid in advance, pooled across indi-
viduals, and sustainable, is essential. Donors can play a role
in supporting these systems, but government commitment, re-
sources, and leadership are of the utmost importance.
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Reasons for Increases in Complications of Diabetes
To the Editor Dr Gregg and colleagues1 identified a resurgence
in diabetes complications in the United States beginning in
2010 and analyzed potential underlying contributors and policy
implications. However, there may be another underlying me-
diator of the effect that the authors did not consider.
There has been a decline in the incidence of diabetes that
began in approximately 2009.2,3 With changes in the diagnos-
tic criteria and emphasis on screening for diabetes over the last
2 decades, US clinicians likely diagnosed a large number of pre-
viously unrecognized cases in the earlier part of this century.
This increased identification may have artifactually reduced
the rate of complications because of a bolus of relatively early
cases of diabetes. Now that diagnostic behaviors are more
stable, the proportion of recently diagnosed patients among
the population with diabetes is less than a decade ago, lead-
ing to the appearance of a phenotype of more complications.
A related phenomenon is that the duration of diabetes at
a given age may be driving the increase in complications, which
is most evident in the emergence of type 2 diabetes in youth
and increasing rates of diabetes in younger adults. Likely driven
by the obesity epidemic, people are developing diabetes ear-
lier, and thus someone aged 50 years with diabetes today may
have had the disease for 10 years, whereas a decade ago, they
may have developed the disease later. Neither of these possi-
bilities diminish the urgency with which these trends should
be further examined and addressed.
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In Reply We agree with Dr Buse’s potential explanation of our
findings1 that the changing characteristics of the underlying
population could be a key factor, particularly affected by a shift
in the duration of disease. Data from the US National Diabe-
tes Surveillance System indicate that the median duration of
disease increased by 2 years between 2010 and 2016 (from a
median of 7.4 years to 9.4 years).2 The shifting distribution of
duration of disease may also have multiple causes.
In addition to those noted by Buse (screening, testing, and
diagnostic thresholds), declining mortality rates in both middle
and older age groups are increasing the proportion of persons
with long-standing diabetes.3 However, the increase in
median duration of disease was modest in adults aged 18 to
44 years (0.6 years) compared with those aged 45 to 64 years
(1.7 years) and those aged 65 to 74 years (2.5 years).2
Thus, it seems unlikely that the changing duration of dis-
ease explains the difference in trends between young adults
and older adults, and we agree with Buse that better under-
standing of the heterogeneity of obesity and young-onset dia-
betes is crucial because of the implications for the future bur-
den of diabetes complications. Unfortunately, the degree to
which each of these factors affects diabetes complication rates
has not been properly quantified, and existing national data
on hospitalizations lack the information to do so. As we noted
in our Viewpoint, the effect of health care access, delivery, and
preventive care also remain inadequately quantified despite
being potentially powerful levers for positive change.
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Challenges of Dual-Physician Couples
To the Editor We agree with Drs Ferrante and Mody that dual-
physician households face professional and personal challenges.1
However, we are chagrined by their view that dual-physician
couples are unique or in greater need of “21st-century strategies”
for dealing with life challenges than other professional women.
All working women, whether single, married, or in a committed
relationship, and whether they do or do not have children, con-
front the difficulties of achieving economic stability and work-
life balance. Dual-physician couples are not alone in struggling
with student loan debt, weighing child-bearing decisions with
professional advancement, or trying to fulfill personal and pro-
fessional goals despite inadequate support or guidance.
The authors’ proposals to focus additional funding and sys-
tems only on dual-physician couples could potentially disad-
vantage other populations that are already underrepresented
or underserved in professional medicine. For example, single
female and homosexual physicians who want a family while
continuing to pursue career goals would also benefit from the
authors’ strategies.
The early career process for any recent graduate of a post-
baccalaureate education, profession, or training program, is
fraught with the need to make personal and professional de-
cisions. Unlike other recently graduated professional couples
who must negotiate individual career and relocation oppor-
tunities, dual-physician couples have the option of prioritiz-
ing partner geographic proximity or training site desirability.
The National Resident Matching Program, which does not ex-
ist in similar demanding professions, already successfully fa-
cilitates couples’ personal and professional alignment.
Because the program is voluntary, couples may decline en-
rolling if, for instance, they choose to prioritize maximization
of individual training site assignment. Such a choice might in-
clude consideration by both partners to become a commuter
couple, not dissimilar to many other professional couples.
Changing career demographics for men and women will
likely lead to the emergence of a critical mass of effective role
models who have successfully navigated the challenges of
balancing personal and professional aspirations. Until this
critical mass is established, we propose expansion of second-
ary education career counseling to include information
regarding inherent benefits and challenges of career and life-
style choices and pathways to balance these possibilities.
Conversations during adolescence would foster early engage-
ment of young adults in open communication and necessary
forethought about professional and personal goals with the
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